Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent BioBlast® Updates

Novo Nordisk’s Wegovy® (Semaglutide) Reduces Dementia Risk

Jul 10, 2024

Novo Nordisk’s Wegovy® (semaglutide) known for treating diabetes, weight loss benefits, and reducing cardiovascular events and kidney disease risks, has been shown in a University of Oxford study, supported by the NIHR Oxford Health Biomedical Research Centre and the...

Bio Farma Partners with Novo Nordisk to Package Insulin in Indonesia

Jul 9, 2024

Novo Nordisk has reportedly struck a deal with Indonesia’s state-owned pharmaceutical company Bio Farma regarding the packaging of insulin in Indonesia.  This is the first of Novo Nordisk's packaging deals in Indonesia for insulin, which is manufactured in Denmark and...

Aflibercept Patent PTAB Invalidity Decision Appeals Dismissed

Jul 9, 2024

On 9 July 2024, Regeneron, Mylan, Celltrion and Apotex agreed to the dismissal of Regeneron’s appeals in the US Court of Appeal for the Federal Circuit from PTAB decisions finding US Patent Nos. 9,254,338 and 9,669,069 invalid.  The patents encompass Regeneron’s...

Just – Evotec Biologics and Sandoz Expand Biosimilars Partnership

Jul 8, 2024

On 8 July 2024, Just – Evotec, a subsidiary of Evotec SE, announced that it has expanded its partnership with Sandoz to develop and manufacture multiple biosimilars.  The deal was first entered into in May 2023 and is designed to utilise Just – Evotec's AI driven drug...

Eli Lilly to Acquire Morphic Holding in $3.2B Deal

Jul 8, 2024

On 8 July 2024, Eli Lilly and Morphic Holding announced that Eli Lilly has agreed to acquire Morphic for US $3.2b.  Morphic Holding is a US biopharmaceutical company developing oral integrin therapies for treating chronic diseases.  The acquisition has been approved...

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here